目的:评价哌拉西林钠/他唑巴坦治疗老年脑卒中急性期中、重度肺部感染的临床疗效及安全性。方法:回顾性分析2010年4月至2011年4月辽宁省沈阳市红十字会医院收治的76例老年脑卒中急性期中、重度肺部感染患者的临床资料,按治疗方式不同分为观察组(40例)和对照组(36例),观察组给予哌拉西林钠/他唑巴坦钠4.5g静脉滴注,2次/d;对照组给予头孢唑肟3 g静脉滴注,2次/d,疗程10～14 d,2周后观察两组患者的临床疗效、细菌清除率等。结果:观察组与对照组总有效率、治愈率分别为为90%、72%与72%、50%,两组比较,差异有统计学意义(P<0.05)。观察组与对照组细菌清除率分别为80%与56%,两组比较差异有统计学意义(P<0.05)。结论:哌拉西林钠/他唑巴坦安全、抗菌谱广,在老年脑卒中急性期中、重度肺部感染治疗中疗效显著,值得推荐使用。 OBJECTIVE: To evaluate the clinical efficacy and safety of piperacillin / tazobactam in the treatment of moderate and severe acute lung infection in elderly patients with stroke. Methods: The clinical data of 76 elderly patients with moderate and severe acute stroke who were admitted to Shenyang Red Cross Hospital from April 2010 to April 2011 were retrospectively analyzed. According to the different treatment methods, the patients were divided into observation group 40 cases) and control group (36 cases). The observation group was given 4.5g piperacillin sodium / tazobactam sodium intravenous infusion twice a day, the control group was given ceftizoxime 3g intravenous infusion, 2 times / d, treatment 10 ~ 14 d, 2 weeks after the observation of the clinical efficacy of two groups of patients, such as bacterial clearance rate. Results: The total effective rate and the cure rate of the observation group and the control group were 90%, 72% and 72%, 50% respectively. There was significant difference between the two groups (P <0.05). The bacterial clearance rates in observation group and control group were 80% and 56%, respectively, with significant difference between the two groups (P <0.05). CONCLUSION: Piperacillin / tazobactam is safe and has a broad antimicrobial spectrum. It is highly recommended in the treatment of severe pulmonary infections in the acute stage of elderly stroke.